NEW YORK (GenomeWeb News) – National managed healthcare company WellPoint has revised its medical policy regarding non-invasive fetal aneuploidy screening, suggesting that it will begin covering tests such as Sequenom's MaterniT21 Plus test.

News of the change by WellPoint sent shares of Sequenom up as much as 9 percent today on the Nasdaq with the number of shares traded more than double Sequenom's average daily volume during the past three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.